公开(公告)号：EP2499161B8

公开(公告)日：2017-10-25

申请号：EP10778877.0

申请日：2010-11-11

申请人： Ganymed Pharmaceuticals GmbH ,  Johannes Gutenberg-Universität Mainz

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  KOSLOWSKI, Michael ,  WALTER, Korden ,  WÖLL, Stefan ,  KREUZBERG, Maria ,  HUBNER, Bernd ,  ERDELJAN, Michael

IPC分类号： C07K16/28 ,  C07K14/705 ,  A61P35/00 ,  A61K39/00 ,  C07K16/30

CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734

摘要： The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

公开(公告)号：EP2618835B1

公开(公告)日：2017-07-05

申请号：EP11761508.8

申请日：2011-09-19

申请人： BioNTech Cell & Gene Therapies GmbH ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  SIMON, Petra ,  OMOKOKO, Tana

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K14/47 ,  C07K14/045

CPC分类号： A61K39/0011 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/57 ,  C07K14/005 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C12N5/0636 ,  C12N9/16 ,  C12N15/85 ,  C12N2510/00 ,  C12N2710/16134 ,  C12Y301/03048 ,  G01N33/5017 ,  G01N2333/916

摘要： The present invention relates to efficient methods for providing antigen- specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.

摘要翻译： 本发明涉及提供抗原特异性淋巴细胞的有效方法。 这些淋巴细胞可用于提供具有限定的MHC限制的抗原特异性T细胞受体并鉴定免疫学相关的T细胞表位。 此外，本发明涉及抗原特异性T细胞受体和T细胞表位及其在免疫治疗中的用途。

公开(公告)号：EP2069538B1

公开(公告)日：2015-07-08

申请号：EP07818850.5

申请日：2007-10-09

申请人： BioNTech AG ,  Johannes Gutenberg-Universität Mainz, vertreten durch den Präsidenten

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  KOSLOWSKI, Michael

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  A61K31/7088 ,  A61K39/39558 ,  A61K47/6807 ,  C07K16/28 ,  C07K16/2866 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1138 ,  C12N15/8218 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/715 ,  G01N2333/7158 ,  G01N2333/916

公开(公告)号：EP2370101B8

公开(公告)日：2013-05-01

申请号：EP09796949.7

申请日：2009-12-09

申请人： BioNTech AG ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  KREITER, Sebastian ,  SELMI, Abderraouf

IPC分类号： A61K39/39 ,  C07K14/475

CPC分类号： A61K39/39 ,  A61K2039/53 ,  A61K2039/55516 ,  C07K14/475 ,  C07K2319/00

公开(公告)号：EP4364756A2

公开(公告)日：2024-05-08

申请号：EP24150410.9

申请日：2013-05-21

申请人： Astellas Pharma Inc. ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  MITNACHT-KRAUS, Rita ,  JACOBS, Denis Stefan ,  UTSCH, Magdalena Jadwiga ,  HEINZ, Cornelia Adriana Maria ,  STADLER, Christiane Regina

IPC分类号： A61K45/06

CPC分类号： A61K39/39558 ,  A61K45/06 ,  C07K16/30 ,  C07K16/3046

摘要： The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

公开(公告)号：EP3795177A1

公开(公告)日：2021-03-24

申请号：EP20193185.4

申请日：2016-05-09

申请人： BioNTech Cell & Gene Therapies GmbH ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  SIMON, Petra ,  OMOKOKO, Tana ,  BREITKREUZ, Andrea ,  MROZ, Karolina Anna ,  HEBICH, Lisa

IPC分类号： A61K39/395 ,  C07K14/725 ,  C07K7/06 ,  C07K14/47 ,  A61P35/00

摘要： The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

公开(公告)号：EP3766903A2

公开(公告)日：2021-01-20

申请号：EP20189087.8

申请日：2013-11-12

申请人： BioNTech SE ,  Astellas Pharma Inc. ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  STADLER, Christiane ,  HOLLAND, Julia ,  BÄHR-MAHMUD, Hayat ,  BEISSERT, Tim ,  PLUM, Laura ,  LE GALL, Fabrice ,  JENDRETZKI, Arne ,  FIEDLER, Markus

IPC分类号： C07K16/28

摘要： The present disclosure provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

公开(公告)号：EP3738612A1

公开(公告)日：2020-11-18

申请号：EP20181374.8

申请日：2014-07-30

申请人： Biontech AG ,  Astellas Pharma Inc. ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  WALTER, Korden ,  WAGNER, Meike ,  KREUZBERG, Maria ,  HÄCKER, Sabine ,  JACOBS, Stefan

IPC分类号： A61K39/395 ,  G01N33/50 ,  G01N33/569 ,  G01N33/574

摘要： The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

公开(公告)号：EP3708579A1

公开(公告)日：2020-09-16

申请号：EP20160141.6

申请日：2015-03-30

申请人： BIONTECH CELL & GENE THERAPIES GMBH ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH ,  Ganymed Pharmaceuticals GmbH

发明人： SAHIN, Ugur ,  TÜRECI, Özlem ,  OEHM, Petra ,  OMOKOKO, Tana ,  HOFF, Holger ,  VOSS, Ralf-Holger ,  BREITKREUZ, Andrea ,  HOBOHM, Kathleen ,  MROZ, Karolina Anna

IPC分类号： C07K14/725 ,  C07K14/47 ,  A61P35/00 ,  A61K35/26

摘要： The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

公开(公告)号：EP3670537A1

公开(公告)日：2020-06-24

申请号：EP19210913.0

申请日：2014-03-17

申请人： Astellas Pharma Inc. ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH

发明人： SAHIN, Ugur ,  TÜRECI, Özlem

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61P35/00

摘要： The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN 18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.